GPP
JNCE

Great Point Partners’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Great Point Partners’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-292,673
Closed -$3.73M – 46
2017
Q4 		$3.73M Buy
+292,673
New +$4.3M 0.64% 33

Other funds holding JNCE

TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Great Point Partners's JNCE Position: Q1 2018 in Review

Great Point Partners sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q1 2018, closing a stake of 292,673 shares — an estimated $3.73M sold.

Great Point Partners first reported a position in JNCE in Q4 2017 and held it in 1 quarter. The position peaked at $3.73M in Q4 2017. 94 funds tracked by Wall St. Rank hold JNCE as of Q1 2018.

  • Great Point Partners reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Great Point Partners sold 292,673 Jounce Therapeutics, Inc. Common Stock shares in Q1 2018, an estimated $3.73M.
  • Great Point Partners first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2017 and held it in 1 quarter.
  • Great Point Partners's Jounce Therapeutics, Inc. Common Stock position peaked at $3.73M in Q4 2017.
  • 94 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2018.

Based on Great Point Partners's 13F filing for Q1 2018, filed 14 May 2018.